Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Cortes

Showing results (211-220 of 232) with videos related to

Pageof 24
Sort By:
Oncotarget|May 15, 2018
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastasesLeticia De Mattos-Arruda, Charlotte K Y Ng, Salvatore Piscuoglio, et al.
Cancer Research Communications|September 15, 2023
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other TumorsGlenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, et al.
JCO Global Oncology|September 8, 2020
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to ArmsKamal S Saini, Begoña de Las Heras, Ruth Plummer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Science Translational Medicine|April 17, 2015
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancerAna Bosch, Zhiqiang Li, Anna Bergamaschi, et al.
Oncotarget|April 21, 2017
Critically short telomeres and toxicity of chemotherapy in early breast cancerMiguel Quintela-Fandino, Nora Soberon, Ana Lluch, et al.
Cancer Treatment Reviews|October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancerFrancesco Schettini, Sergio Venturini, Mario Giuliano, et al.
Breast Cancer Research : BCR|December 5, 2019
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2<sup>+</sup> breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
Breast Cancer Research : BCR|January 24, 2020
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2016
<sup>18</sup>F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized TrialMiguel Quintela-Fandino, Ana Lluch, Luis Manso, et al.
Pageof 24

Showing results (211-220 of 232) with videos related to

Sort By:
Pageof 24
Oncotarget|May 15, 2018
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastasesLeticia De Mattos-Arruda, Charlotte K Y Ng, Salvatore Piscuoglio, et al.
Cancer Research Communications|September 15, 2023
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other TumorsGlenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, et al.
JCO Global Oncology|September 8, 2020
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to ArmsKamal S Saini, Begoña de Las Heras, Ruth Plummer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Science Translational Medicine|April 17, 2015
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancerAna Bosch, Zhiqiang Li, Anna Bergamaschi, et al.
Oncotarget|April 21, 2017
Critically short telomeres and toxicity of chemotherapy in early breast cancerMiguel Quintela-Fandino, Nora Soberon, Ana Lluch, et al.
Cancer Treatment Reviews|October 6, 2022
Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancerFrancesco Schettini, Sergio Venturini, Mario Giuliano, et al.
Breast Cancer Research : BCR|December 5, 2019
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2<sup>+</sup> breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
Breast Cancer Research : BCR|January 24, 2020
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2016
<sup>18</sup>F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized TrialMiguel Quintela-Fandino, Ana Lluch, Luis Manso, et al.
Pageof 24